SLC5A2 and diabetes mellitus: Also, SGLT2 inhibition by empagliflozin in myocardial infarction mouse models with and without DM demonstrated a reduced infarct size and myocardial fibrosis mediated by inhibiting the autophagic flux in the cardiomyocytes [324].